Advicenne
Financials
Estimates*
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.0m | 4.0m | 3.0m | 2.0m | 2.9m | 4.7m | 5.7m |
| % growth | 200 % | 33 % | (25 %) | (33 %) | 47 % | 60 % | 21 % |
| EBITDA | (14.0m) | (14.0m) | (12.0m) | (10.0m) | (2.0m) | (6.7m) | 26.8m |
| % EBITDA margin | (467 %) | (350 %) | (400 %) | (500 %) | (68 %) | (143 %) | 467 % |
| Profit | (14.0m) | (15.0m) | (12.0m) | (11.0m) | (7.0m) | (8.1m) | 22.3m |
| % profit margin | (467 %) | (375 %) | (400 %) | (550 %) | (239 %) | (172 %) | 389 % |
| EV / revenue | 18.3x | 20.3x | 31.3x | 27.9x | 15.3x | 6.6x | 1.9x |
| EV / EBITDA | -3.9x | -5.8x | -7.8x | -5.6x | -22.6x | -4.6x | 0.4x |
| R&D budget | 2.0m | 3.0m | - | - | - | - | - |
| R&D % of revenue | 67 % | 75 % | - | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | €16.0m | Growth Equity VC | |
| N/A | €27.0m Valuation: €112m | IPO | |
* | €7.5m | Post IPO Debt | |
| N/A | €9.4m | Post IPO Equity | |
* | €5.0m | Post IPO Debt | |
| Total Funding | €16.0m | ||
Recent News about Advicenne
EditAdvicenne is a pharmaceutical company focused on developing and commercializing innovative treatments for rare renal diseases. The company serves both children and adults, addressing high unmet medical needs in the healthcare market. Advicenne operates primarily in Europe and the United States, with its headquarters in Paris. The company's business model revolves around the reformulation and delivery of groundbreaking medicines, leveraging its expertise to create products that improve daily health and life. Advicenne generates revenue through the sale of its approved medications, such as the combination of Potassium citrate and Potassium bicarbonate, which received approval from the European Medicine Agency and MHRA in 2021. Listed on Euronext Growth (Euronext ALDVI) since 2022, Advicenne continues to expand its portfolio and market reach.
Keywords: rare renal diseases, innovative treatments, pharmaceutical, reformulation, drug delivery, children and adults, high unmet medical need, quality of life, European Medicine Agency, Euronext Growth.